Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Agilent received EU certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The approval marks the eighth CE-marked indication for this diagnostic, identifying patients eligible for treatment with Merck’s KEYTRUDA based on the KEYNOTE-B96/ENGOT-ov65 trial.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.